Overview

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is the first clinical study with the BMS-986147 compound in healthy subjects. The purpose of this study is to guide the dose range and dose frequency for future studies with BMS-986147 and will provide guidelines for selection of a potentially effective dose in patients.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb